Literature DB >> 19856059

Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.

Yasuhisa Hasegawa1, Koji Mita, Akio Matsubara, Hideki Ohdan.   

Abstract

We report a case of metastatic renal cell carcinoma in the native kidney of a renal transplant recipient. The patient was a 57-year-old man in whom a tumor in the native kidney and bone metastasis were found incidentally on imaging, 10 years after cadaveric renal transplantation. Interferon-alpha was administered after nephrectomy and following palliative irradiation of the metastasis, but could not be continued because of allograft dysfunction. Subsequent administration of zoledronic acid and sorafenib stabilized the disease for 18 months after nephrectomy. This is the first reported case of sorafenib administration to a renal transplant recipient with metastatic renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856059     DOI: 10.1007/s10147-008-0868-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  18 in total

1.  De novo renal cell carcinoma of native kidney in renal transplant recipients.

Authors:  Yann Neuzillet; Franck Lay; Aline Luccioni; Laurent Daniel; Yvon Berland; Christian Coulange; Eric Lechevallier
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Metastatic renal cell carcinoma arising in a native kidney of a renal transplant recipient.

Authors:  T Nakamoto; M Igawa; S Mitani; M Ueda; A Usui; T Usui
Journal:  J Urol       Date:  1994-09       Impact factor: 7.450

4.  Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years.

Authors:  T Hanafusa; Y Ichikawa; H Kishikawa; M Kyo; T Fukunishi; Y Kokado; A Okuyama; Y Shinji; S Nagano
Journal:  Transplantation       Date:  1998-08-27       Impact factor: 4.939

Review 5.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz
Journal:  Oncologist       Date:  2007-04

6.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

7.  Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin.

Authors:  Sydney Tang; Ignatius K P Cheng; Vincent K S Leung; Un I Kuok; Anthony W C Tang; Yiu Wing Ho; Kar Neng Lai; Tak Mao Chan
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

8.  Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

Authors:  Allan Lipton; Ming Zheng; John Seaman
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

9.  Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.

Authors:  Martin Haas; Zdenka Leko-Mohr; Paul Roschger; Josef Kletzmayr; Christoph Schwarz; Christa Mitterbauer; Rudolf Steininger; Stefan Grampp; Klaus Klaushofer; Günter Delling; Rainer Oberbauer
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  3 in total

1.  Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report.

Authors:  Fumiya Hongo; Masakatsu Oishi; Takashi Ueda; Yasuyuki Naitoh; Terukazu Nakamura; Yoshio Naya; Kazumi Kamoi; Koji Okihara; Tsuneharu Miki
Journal:  BMC Res Notes       Date:  2014-08-13

Review 2.  Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review.

Authors:  Dag Olav Dahle; Morten Skauby; Carl Wilhelm Langberg; Knut Brabrand; Nicolai Wessel; Karsten Midtvedt
Journal:  Transplantation       Date:  2022-01-01       Impact factor: 5.385

Review 3.  Skeletal metastasis in renal cell carcinoma: A review.

Authors:  Masood Umer; Yasir Mohib; Muhammed Atif; Muhammad Nazim
Journal:  Ann Med Surg (Lond)       Date:  2018-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.